Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S D Allen

Showing results (131-140 of 149) with videos related to

Pageof 15
Sort By:
Annals of the New York Academy of Sciences|January 1, 1988
cis-5-alkyl(or alkenyl)-3-phenyl-3-(1H-imidazole-1-ylmethyl)-2- methylisoxazolidine derivatives. In vitro antifungal activity and structure-activity relationshipsP A Swift, G A Bennett, G B Mullen, et al.
Journal of Clinical Microbiology|November 1, 1996
Multicenter evaluation of four methods for Clostridium difficile detection: ImmunoCard C. difficile, cytotoxin assay, culture, and latex agglutinationJ L Staneck, L S Weckbach, S D Allen, et al.
Journal of Clinical Microbiology|April 1, 1993
Controlled comparison of the BACTEC high-blood-volume fungal medium, BACTEC Plus 26 aerobic blood culture bottle, and 10-milliliter isolator blood culture system for detection of fungemia and bacteremiaM L Wilson, T E Davis, S Mirrett, et al.
Diagnostic Microbiology and Infectious Disease|August 1, 1992
Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelinesE H Gerlach, R N Jones, S D Allen, et al.
Archiv Der Pharmazie|September 1, 1989
Antifungal activity of novel 5-carbonyl derivatives of 3-phenyl-3-(1H-imidazol-1-ylmethyl)-2-methylisoxazolidinesG A Bennett, G B Mullen, T R DeCory, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 1, 1991
Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolatesP R Murray, S D Allen, M E Erwin, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1991
In vitro comparison of GR69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolatesJ A Washington, R N Jones, S D Allen, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|February 8, 2013
Cutaneous presentation of progressive disseminated histoplasmosis nine years after renal transplantationV M Rosado-Odom, J Daoud, R Johnson, et al.
Journal of Clinical Microbiology|September 1, 1993
Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parametersA L Barry, P C Fuchs, S D Allen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
Comparisons of ketoconazole, PR 969-566, PR 967-234, and PR 967-248 as antifungals in vitro and in the rat model of candidal vaginitis based on efficacy/safety profilesG C Palmer, J M Ordy, R D Simmons, et al.
Pageof 15

Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
Annals of the New York Academy of Sciences|January 1, 1988
cis-5-alkyl(or alkenyl)-3-phenyl-3-(1H-imidazole-1-ylmethyl)-2- methylisoxazolidine derivatives. In vitro antifungal activity and structure-activity relationshipsP A Swift, G A Bennett, G B Mullen, et al.
Journal of Clinical Microbiology|November 1, 1996
Multicenter evaluation of four methods for Clostridium difficile detection: ImmunoCard C. difficile, cytotoxin assay, culture, and latex agglutinationJ L Staneck, L S Weckbach, S D Allen, et al.
Journal of Clinical Microbiology|April 1, 1993
Controlled comparison of the BACTEC high-blood-volume fungal medium, BACTEC Plus 26 aerobic blood culture bottle, and 10-milliliter isolator blood culture system for detection of fungemia and bacteremiaM L Wilson, T E Davis, S Mirrett, et al.
Diagnostic Microbiology and Infectious Disease|August 1, 1992
Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelinesE H Gerlach, R N Jones, S D Allen, et al.
Archiv Der Pharmazie|September 1, 1989
Antifungal activity of novel 5-carbonyl derivatives of 3-phenyl-3-(1H-imidazol-1-ylmethyl)-2-methylisoxazolidinesG A Bennett, G B Mullen, T R DeCory, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 1, 1991
Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolatesP R Murray, S D Allen, M E Erwin, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1991
In vitro comparison of GR69153, a novel catechol-substituted cephalosporin, with ceftazidime and ceftriaxone against 5,203 recent clinical isolatesJ A Washington, R N Jones, S D Allen, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|February 8, 2013
Cutaneous presentation of progressive disseminated histoplasmosis nine years after renal transplantationV M Rosado-Odom, J Daoud, R Johnson, et al.
Journal of Clinical Microbiology|September 1, 1993
Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parametersA L Barry, P C Fuchs, S D Allen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
Comparisons of ketoconazole, PR 969-566, PR 967-234, and PR 967-248 as antifungals in vitro and in the rat model of candidal vaginitis based on efficacy/safety profilesG C Palmer, J M Ordy, R D Simmons, et al.
Pageof 15